8 08, 2024

Eli Lilly Climbs 8% on Impressive Earnings and Upbeat Outlook as Drug Sales Surge: Time to Buy?

By |2024-08-08T16:23:03+00:00August 8th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , |

Eli Lilly & Co. (LLY) is up more than 8% so far Thursday morning after reporting second-quarter earnings that easily surpassed the Wall Street consensus. The company also raised its guidance for the full year. The drugmaker posted adjusted earnings per share of $3.92, well ahead of the $2.60 that was expected by analysts. [...]

26 06, 2023

Eli Lilly is Up 38% in the Past 3 Months: What Keeps Pushing the Stock Higher, and Will it Continue?

By |2023-08-02T19:10:25+00:00June 26th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , |

While much of the recent focus within the stock market has been placed on the AI trend, one stock in the pharmaceutical industry has been on a surge so far this year: Eli Lilly (LLY). The stock sat at just $311/share at the start of March. And today, the stock sits at $452/share. But, [...]

26 06, 2023

Eli Lilly is Up 38% in the Past 3 Months: What Keeps Pushing the Stock Higher, and Will it Continue?

By |2023-06-26T15:46:53+00:00June 26th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , |

While much of the recent focus within the stock market has been placed on the AI trend, one stock in the pharmaceutical industry has been on a surge so far this year: Eli Lilly (LLY). The stock sat at just $311/share at the start of March. And today, the stock sits at $452/share. But, [...]

23 09, 2022

LLY is Upgraded by Analysts Ahead of New Drug…But What Does VectorVest Rate the Stock?

By |2023-08-02T19:17:08+00:00September 23rd, 2022|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , |

You’d be hard-pressed to find a stock that’s shown positive growth over the past year - but Eli Lilly is one of them. The pharmaceutical developer & manufacturer has had a great year - up 35% in the last 365 days. Even looking at the bigger picture, this stock has been a high-performer. This [...]

Go to Top